Synthesis and structure–activity relationships of a new class of selective EP 3 receptor agonist, 13,14-didehydro-16-phenoxy analogues of prostaglandin E 1
A series of 13,14-didehydro-16-phenoxy analogues of prostaglandin E1 was synthesized and their agonistic activity on EP receptor subtypes was evaluated. 13,14-Didehydro-16-phenoxy-1-decarboxy analogues, 7e and 7f, display highly selective activity on the EP3 receptor subtype, thus, their utility as a selective anti-ulcer agent can be expected.
Hydroxyalkylcysteine derivative and expectorant containing the same
申请人:SS PHARMACEUTICAL CO., LTD.
公开号:EP0346882A2
公开(公告)日:1989-12-20
Novel hydroxyalkylcysteine derivatives of the following formula (I) and an expectorant comprising the same are disclosed.
wherein n represents an integer of 5 to 24. The expectorant is stabile, has little side effects and toxicity, and exhibits an excellent expectorant effect.
本发明公开了下式(I)的新型羟烷基半胱氨酸衍生物以及由其组成的祛痰剂。
其中 n 代表 5 至 24 的整数。该祛痰剂性质稳定,副作用和毒性小,并具有良好的祛痰效果。
Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
申请人:Tong Xiao
公开号:US20070274951A1
公开(公告)日:2007-11-29
Disclosed are medicaments, pharmaceutical compositions, pharmaceutical kits, and methods based on combinations of at least one HCV protease inhibitor and at least one HCV polymerase inhibitor but not HCV-796; for concurrent or consecutive administration in treating or ameliorating one or more symptoms of HCV, or disorders associated with HCV in a subject in need thereof.